drugset / Trial / NCT00388882

Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.

NCT00388882

Phase 4 Completed 327 enrolled Boehringer Ingelheim
Treatment

Summary

The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotro pium HandiHaler® 18 mcg daily compared to Combivent® MDI CFC Inhalation Aerosol 2 actuations qid in COPD patients currently prescribed Combivent® MDI.

Timeline

Start
2006-10-04
Primary completion
2007-10-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipratropium Small molecule Inhaled
Subject Salbutamol Unknown Inhaled
Subject Tiotropium Other / unclassified 18 ug Inhaled